Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCTc030200051
JPRN-jRCTc030200051
Recruiting
Phase 1

Evaluation of immune cell therapy with standard treatment for pediatric patients with malignant brain tumor.

Kondo Akihide0 sites3 target enrollmentJune 15, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMalignant brain tumor

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Malignant brain tumor
Sponsor
Kondo Akihide
Enrollment
3
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 15, 2020
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Kondo Akihide

Eligibility Criteria

Inclusion Criteria

  • •(1\)Diagnosed with malignant brain tumor.
  • •(2\)Patients scheduled to receive surgical resection, radiotherapy and chemotherapy as standard treatment.
  • •(3\)70 or over of Karnofsky Performance Status (KPS) or Lansky Performance Status (LPS) score.
  • •(4\)Life expectancy more than 2 months after initiation of the study therapy.
  • •(5\)Age ranging over 3 years old and under 15 years old.
  • •(6\)Possible to visit outpatient department.
  • •(7\)Adequate function of liver, kidney, and bone marrow when eligibility is confirmed.
  • •(8\)Written informed consent of guardian to participate this study.

Exclusion Criteria

  • •(1\)Apparent from the clinical manifestation of pulmonary fibrosis or interstitial pneumonia.
  • •(2\)A history of a serious drug allergy.
  • •(3\)Positive result of HIV or HTLV\-1 antibody test.
  • •(4\)A serious cardiac disorder.
  • •(5\)Active autoimmune disorder.
  • •(6\)Cancers other than malignant brain tumor.
  • •(7\)An infectious disorder that is difficult to control.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 1
A phase I clinical study of immune cell therapy with MAGE-A4- or Survivin-specific Th1 cells for patients with refractory virulent tumorsRefractory cancer patients (MAGE-A4- or Survivin-expressing, non origin-limited) or the patients who refuse standard cancer therapy
JPRN-UMIN000004828Department of General Surgery, Hokkaido University Graduated School of Medicine18
Completed
Phase 1
A novel cell therapy to treat patients with hepatitis C virus (HCV)infection.Hepatitis C virus infectionOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonInfection - Other infectious diseasesInflammatory and Immune System - Normal development and function of the immune system
ACTRN12610000067077Eric J Gowans15
Not yet recruiting
Not Applicable
Investigate the safety and efficacy of small cell lung cancer,Kidney cancer and Primary liver cancer immunotherapyHistopathologically confirmed small cell lung cancer (SCLC)Histopathologically confirmed Kidney cancerHistopathologically confirmed Liver cancer
ACTRN12618001337268The First Teaching Hospital, Inner Mongolia Medical University50
Active, not recruiting
Phase 1
Study on an Investigational Yellow Fever Vaccine Compared with Stamaril in Adults in Europe and AsiaYellow feverMedDRA version: 20.0Level: PTClassification code: 10048240Term: Yellow fever Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]
CTIS2022-502047-35-00Sanofi Pasteur690
Active, not recruiting
Phase 1
Study on an Investigational Yellow Fever Vaccine Compared with Stamaril in Adults in Europe and Asia
EUCTR2020-005566-33-DESanofi Pasteur690